CGTX - Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
- An analysis of biomarker data from Cognition Therapeutics' ( NASDAQ: CGTX ) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes.
- Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40.
- The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's.
- Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.
For further details see:
Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar